Reforming Biopharmaceutical Pricing at Home and Abroad

November 23, 2017

The affordability of healthcare and biopharmaceutical drugs is a top concern for Americans. It is often asserted that promoting innovation and affordable drugs are conflicting goals. New innovations, however, often provide improved health that was not previously available at any price or obviate the need for more costly care. They thereby lower the effective price of health down to the price of the patented drugs, and later down to the price of generic drugs. Federal policies that affect drug pricing should satisfy two goals.

Spotlight

Vel Vaccines Biosciences

VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.

OTHER WHITEPAPERS
news image

The Key to Commercializing Revolutionary Gene Therapiesand Other Orphan Drugs

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery

Read More
news image

Modernizing Pharma Operations With Process Analytical Technology

whitePaper | November 18, 2022

It’s the same for manufacturers across industries and across the globe; there’s a steadily increasing pressure to meet market demand, despite facing new challenges andconstraints.

Read More
news image

Pharma R And D Review

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

Read More
news image

Getting serious about serialization: A comprehensive look at thelegislation shaping U.S. pharmaceutical supply chains

whitePaper | October 7, 2022

The Drug Supply Chain Security Act is one component of the DQSA. This particular act requires the FDA to implement a national track-and-trace system by which manufacturers must affix product identifiers (barcodes) to each package of product that is introduced into the supply chain.

Read More
news image

Three Challenges Facing Study Start Up and the Low-Code Solution

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More

Spotlight

Vel Vaccines Biosciences

VEL (Variable Epitope Library) vaccine technology was developed to address the need for effective immunization strategies against antigenically variable targets. The main limitation of current technologies is their inability to elicit sustained, protective immune responses against these constantly changing targets. VEL vaccines anticipate large numbers of mutational outcomes in the target and challenge host immune defenses with thousands and tens of thousands of epitopes. Immune systems primed with VEL-vaccines produce unprecedented repertoires of T-cells capable of containing and neutralizing disease caused by antigenically variable targets.

Events